. 2010 Oct;27(10):1837–1852. doi: 10.1089/neu.2010.1374

Table 2.

Validation of MCAO Differential Neuroproteomic Data and Immunoblot Comparison between Injury Models

			MCAO						TBI
			Gel band^a		Δ Peptide count		Blot band^a		Blot band^a
Protein	Accession no.	Mr (kDa)	30 min	2 h	30 min	2 h	30 min	2 h	1.6 mm
Amphiphysin	O08838	125	–	–	–	–	91%	68%^***	86%
		110	120%	38%	0	−2	110%	44%^**	18%^**
GAPDH	P04797	36	27%	110%	−2	3	93%^*	100%	70%^*
PYGB	P53534	97	54%	20%	−10	−14	86%	50%^***	65%^*
		67^b	–	–	–	–	110%	170%^***	260%^***
NSE	P07323	47	280%	530%	2	4	130%^*	120%^*	67%^*
SNAP25	P60881	23	100%	47%	−1	−3	150%	50%^*	25%^*
Spectrin (α2)	P16086	280	89%	20%	1	−2	86%	44%^*	66%^*
		150^b	140%	460%	0	2	120%	300%^**	370%^***
		145^b	–	–	–	–	130%	430%^***	750%^***
Synapsin	P09951	74	55%	38%	−2	−2	94%	44%^***	27%^***
UCHL1	Q00981	25	100%	50%	2	−2	93%	71%^*	130%

^{^a}

Percent of control value.

^{^b}

Protein breakdown product.

^{^*}

p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 significantly different from sham-operated animals.

MCAO, middle cerebral artery occlusion; TBI, traumatic brain injury; UCHL1, ubiquitin carboxyl-terminal hydrolase L1; SNAP25, synaptosomal-associated protein 25; NSE, neuron-specific enolase; PYGB, glycogen phosphorylase (brain form); GAPDH, glyceraldehyde-3-phosphate dehydrogenase.